Sentinel node biopsy and occult lesion localization in early breast cancer

G. Paganelli, G. Trifirò, L. Ravasi, C. De Cicco

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Sentinel lymph node (SLN) localization and biopsy represent one of the most important recent developments in surgery, which has been reflected in important changes in the management of patients affected by early infiltrating breast carcinoma. Sentinel lymph node biopsy (SLNB) was first applied in melanoma patients by Morton and colleagues (Morton et al. 1992). Subsequently, the technique was proposed as a method of disease staging in breast cancer patients (Giuliano et al. 1997), so that less aggressive surgical treatment would less compromise the patient's quality of life. In fact, removal of axillary nodes in the presence of breast cancer is performed for staging and not with curative intent (Fisher et al. 2002), and axillary dissection (AD) is burdened by a significant rate of immediate and delayed possible complications such as lymphedema, paresthesia, pain and restriction of arm motion (Shaw and Rumball 1990; Kissin et al. 1986). In this context, SLNB has been proposed as an alternative to routine axillary clearance for nodal status determination.

Original languageEnglish
Title of host publicationClinical Nuclear Medicine
PublisherSpringer Berlin Heidelberg
Pages271-278
Number of pages8
ISBN (Print)9783540280255
DOIs
Publication statusPublished - 2007

Fingerprint

Sentinel Lymph Node Biopsy
Breast Neoplasms
Biopsy
Lymphedema
Paresthesia
Dissection
Melanoma
Quality of Life
Pain
cyhalothrin
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Paganelli, G., Trifirò, G., Ravasi, L., & De Cicco, C. (2007). Sentinel node biopsy and occult lesion localization in early breast cancer. In Clinical Nuclear Medicine (pp. 271-278). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-540-28026-2_12

Sentinel node biopsy and occult lesion localization in early breast cancer. / Paganelli, G.; Trifirò, G.; Ravasi, L.; De Cicco, C.

Clinical Nuclear Medicine. Springer Berlin Heidelberg, 2007. p. 271-278.

Research output: Chapter in Book/Report/Conference proceedingChapter

Paganelli, G, Trifirò, G, Ravasi, L & De Cicco, C 2007, Sentinel node biopsy and occult lesion localization in early breast cancer. in Clinical Nuclear Medicine. Springer Berlin Heidelberg, pp. 271-278. https://doi.org/10.1007/978-3-540-28026-2_12
Paganelli G, Trifirò G, Ravasi L, De Cicco C. Sentinel node biopsy and occult lesion localization in early breast cancer. In Clinical Nuclear Medicine. Springer Berlin Heidelberg. 2007. p. 271-278 https://doi.org/10.1007/978-3-540-28026-2_12
Paganelli, G. ; Trifirò, G. ; Ravasi, L. ; De Cicco, C. / Sentinel node biopsy and occult lesion localization in early breast cancer. Clinical Nuclear Medicine. Springer Berlin Heidelberg, 2007. pp. 271-278
@inbook{b8e67d2354f24a3da443a0abcf998aff,
title = "Sentinel node biopsy and occult lesion localization in early breast cancer",
abstract = "Sentinel lymph node (SLN) localization and biopsy represent one of the most important recent developments in surgery, which has been reflected in important changes in the management of patients affected by early infiltrating breast carcinoma. Sentinel lymph node biopsy (SLNB) was first applied in melanoma patients by Morton and colleagues (Morton et al. 1992). Subsequently, the technique was proposed as a method of disease staging in breast cancer patients (Giuliano et al. 1997), so that less aggressive surgical treatment would less compromise the patient's quality of life. In fact, removal of axillary nodes in the presence of breast cancer is performed for staging and not with curative intent (Fisher et al. 2002), and axillary dissection (AD) is burdened by a significant rate of immediate and delayed possible complications such as lymphedema, paresthesia, pain and restriction of arm motion (Shaw and Rumball 1990; Kissin et al. 1986). In this context, SLNB has been proposed as an alternative to routine axillary clearance for nodal status determination.",
author = "G. Paganelli and G. Trifir{\`o} and L. Ravasi and {De Cicco}, C.",
year = "2007",
doi = "10.1007/978-3-540-28026-2_12",
language = "English",
isbn = "9783540280255",
pages = "271--278",
booktitle = "Clinical Nuclear Medicine",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Sentinel node biopsy and occult lesion localization in early breast cancer

AU - Paganelli, G.

AU - Trifirò, G.

AU - Ravasi, L.

AU - De Cicco, C.

PY - 2007

Y1 - 2007

N2 - Sentinel lymph node (SLN) localization and biopsy represent one of the most important recent developments in surgery, which has been reflected in important changes in the management of patients affected by early infiltrating breast carcinoma. Sentinel lymph node biopsy (SLNB) was first applied in melanoma patients by Morton and colleagues (Morton et al. 1992). Subsequently, the technique was proposed as a method of disease staging in breast cancer patients (Giuliano et al. 1997), so that less aggressive surgical treatment would less compromise the patient's quality of life. In fact, removal of axillary nodes in the presence of breast cancer is performed for staging and not with curative intent (Fisher et al. 2002), and axillary dissection (AD) is burdened by a significant rate of immediate and delayed possible complications such as lymphedema, paresthesia, pain and restriction of arm motion (Shaw and Rumball 1990; Kissin et al. 1986). In this context, SLNB has been proposed as an alternative to routine axillary clearance for nodal status determination.

AB - Sentinel lymph node (SLN) localization and biopsy represent one of the most important recent developments in surgery, which has been reflected in important changes in the management of patients affected by early infiltrating breast carcinoma. Sentinel lymph node biopsy (SLNB) was first applied in melanoma patients by Morton and colleagues (Morton et al. 1992). Subsequently, the technique was proposed as a method of disease staging in breast cancer patients (Giuliano et al. 1997), so that less aggressive surgical treatment would less compromise the patient's quality of life. In fact, removal of axillary nodes in the presence of breast cancer is performed for staging and not with curative intent (Fisher et al. 2002), and axillary dissection (AD) is burdened by a significant rate of immediate and delayed possible complications such as lymphedema, paresthesia, pain and restriction of arm motion (Shaw and Rumball 1990; Kissin et al. 1986). In this context, SLNB has been proposed as an alternative to routine axillary clearance for nodal status determination.

UR - http://www.scopus.com/inward/record.url?scp=84892028363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892028363&partnerID=8YFLogxK

U2 - 10.1007/978-3-540-28026-2_12

DO - 10.1007/978-3-540-28026-2_12

M3 - Chapter

AN - SCOPUS:84892028363

SN - 9783540280255

SP - 271

EP - 278

BT - Clinical Nuclear Medicine

PB - Springer Berlin Heidelberg

ER -